Could a diabetes drug slow MS disability? new study investigates.
NCT ID NCT07207148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding GLP-1 agonists (a type of diabetes drug) to the MS medication ocrelizumab can reduce disability progression in people with multiple sclerosis. Researchers will track 100 adults with MS over 72 weeks, measuring changes in walking, hand function, and thinking speed. The goal is to see if this combination can better control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?